Cours suspendu

Communiqués ProSomnus, Inc.

Actions

LAAA

US50535E1082

Equipement et technologie médicale avancés

Marché Fermé - OTC Markets 20:44:35 02/08/2024			Varia. 5j.	Varia. 1 janv.
0,0136 ^USD	-.--%		-.--%	-

13/04	ProSomnus Sleep Technologies obtient l'homologation de classe II de la FDA pour son dispositif RPMO2 contre l'apnée du sommeil	CI
05/08/24	ProSomnus, Inc. Sorti de la faillite	CI

Communiqués

13/04	ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device	GL
07/08/24	ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization	GL
27/06/24	ProSomnus : NOTICE OF HEARING TO CONSIDER CONFIRMATION OF THE CHAPTER 11 PLAN FILED BY THE DEBTORS AND RELATED VOTING AND Form 8 K	PU
30/05/24	ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society	GL
16/05/24	ProSomnus Announces Strong First Quarter 2024 Revenue Growth	GL
16/05/24	ProSomnus : Announces Strong First Quarter 2024 Revenue Growth - Form 8-K	PU
13/05/24	ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting	GL
10/05/24	Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices	GL
09/05/24	ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success	GL
02/05/24	ProSomnus : Material Agreement - Form 8-K	PU
26/03/24	ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results	GL
16/03/24	ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call	GL
16/03/24	ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call	AQ
22/02/24	ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea	GL
20/02/24	ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024	AQ
20/02/24	ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024	GL
30/01/24	ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA	AQ
30/01/24	ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA	GL
29/01/24	ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices	AQ
29/01/24	ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices	GL
08/01/24	ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea	AQ
08/01/24	ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea	GL
19/12/23	Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices	AQ
19/12/23	Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices	GL
12/12/23	ProSomnus CEO Len Liptak unveils game-changing device and promising clinical trial results for 2024	AQ